RVMD Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.…
Industry Peers
BiotechnologyKey Statistics
About Revolution Medicines (NASDAQ: RVMD)
›
Revolution Medicines (NASDAQ: RVMD) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 883 employees.
The shares were at 159.43 USD on 19 November 2026, up 168.7% over 52 weeks. Its 52-week range is 58.91 USD to 220.81 USD: the price is 27.8% below the high and 170.6% above the low.
Its market capitalisation is 34.48B USD.
Revolution Medicines reports return on equity of -69.3%.
It holds more cash than debt, a net cash position of 2.44B USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. 24 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 274.68 USD is 72.3% above the current price. The next earnings report is expected on 24 February 2027.